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Abstract
Background: Exertional dyspnea is a hallmark symptom of fibrosing interstitial lung disease (fILD), and oxygen
(O2) desaturation is common among patients with fILD. Supplemental O2 is prescribed to maintain normoxia and
alleviate dyspnea. We sought to better understand the associations between O2 and dyspnea in fILD during the
6-min walk test (6MWT).
Methods: 1326 fILD patients compose the sample group. Borg dyspnea and other 6MWT variables were
compared between subjects who performed the test without (non-users) versus with O2 (users).
Results: There were 812 users and 514 non-users; users were older, more likely to have smoked, had greater body
mass index, and had more severe fILD. Despite a similar 6-min SpO2, users perceived greater dyspnea than non-users
(Borg 3.9 ± 2.0 vs 2.9 ± 1.7, p < 0.0001). Whether subjects became hypoxemic (6-min SpO2 < 89 %) or not during the
walk, the results were the same: users perceived greater dyspnea than non-users (hypoxemic: users 3.5 ± 2.1 vs
non-users 2.7 ± 1.8, p < 0.0001; non-hypoxemic: users 3.4 ± 1.9 vs non-users 2.4 ± 1.6, p < 0.0001). Among subjects
who did not desaturate (SpO2 drop < 4 %), users walked a shorter distance (944.9 ± 367.0 vs 1385.3 ± 322.4 feet,
p < 0.0001) but perceived greater dyspnea than non-users (3.3 ± 1.6 vs 2.3 ± 1.7, p = 0.005). No combination of
potentially influential predictor variables entered in multivariate models explained more than 11 % of the variance in
dyspnea ratings.
Conclusion: Dyspnea is a complex perception, and in patients with fILD, O2 may lessen, but does not resolve, it.
Further research is needed to clarify why fILD patients who use O2 perceive greater levels of dyspnea with activity than
O2 non-users.
Keywords: Interstitial lung disease, Pulmonary fibrosis, Dyspnea, Supplemental oxygen, 6-min walk test
Background
The interstitial lung diseases (ILD) comprise several dif-
fuse parenchymal lung diseases whose causes are un-
known or include exposures (e.g., dust, drug, aerosolized
organic antigen) or underlying connective tissue disease
(CTD). Regardless of cause, fibrotic ILD (fILD) is typic-
ally progressive and incurable. Exertional dyspnea, the
hallmark symptom of fILD, impairs physical functioning
and quality of life (QOL) and is often associated with
peripheral oxygen desaturation (SpO2).
The six-minute walk test (6MWT) is commonly used
as a measure of submaximal exercise capacity in patients
with fILD. Along with distance walked (6MWD), SpO2,
heart rate and dyspnea ratings are often collected as part
of the 6MWT and used to assess disease status. Dys-
pnea—the perception of “breathing discomfort”—is due
to a number of complex physical, psychological, social,
environmental and interwoven physiological factors [1].
In fILD, dyspnea is due to reduced lung compliance,
inability to expand tidal volume in response to respira-
tory drive, as well as the elevated work and oxygen cost
* Correspondence: swigrisj@njc.org
3Interstitial Lung Disease Program, Department of Medicine, National Jewish
Health, 1400 Jackson Street, Denver 80206, Colorado, USA
Full list of author information is available at the end of the article
© 2016 Cao et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cao et al. Multidisciplinary Respiratory Medicine  (2015) 10:37 
DOI 10.1186/s40248-015-0035-y
of breathing [2]. Although dyspnea is a personalized per-
ception, it is experienced and described similarly among
patients with the same respiratory disease. For example,
during symptom-limited incremental cycle exercise tests,
‘unsatisfied inspiratory effort’ and ‘rapid breathing’ are
used to describe dyspnea by patients with fILD—but not
by healthy controls [3]. Investigators have observed that
although patients with fILD desaturated to a greater
degree than patients with chronic obstructive pulmonary
disease (COPD), patients with COPD perceived greater
dyspnea. In that study, SpO2 was an independent pre-
dictor of dyspnea severity in patients with fILD but not
in those with COPD. Among patients with fILD, SpO2
explained only a quarter of the variance in dyspnea
ratings [4].
Although supplemental oxygen (O2) is commonly pre-
scribed to patients with fILD to maintain normoxia, in
hopes of relieving dyspnea (and by extension, improving
physical functioning and QOL), few studies have aimed
to decipher the beneficial effects of O2 in these patients
[5, 6]. Through this study, we sought to examine how dys-
pnea ratings from patients who use O2 compare with
those from patients who do not use O2.
Methods
Study subjects
The study group was composed of 1326 patients with
fILD evaluated at National Jewish Health (NJH) from
January 1, 2008 to December 30, 2014. We formed the
cohort by querying the NJH research database for pa-
tients with fILD who completed at least one 6MWT. Pa-
tients with underlying connective tissue disease (CTD)
were excluded; thus, the overwhelming majority of sub-
jects had idiopathic pulmonary fibrosis (IPF), idiopathic
nonspecific interstitial pneumonia (iNSIP) or chronic
hypersensitivity pneumonia (cHP), with diagnoses made
in accordance with accepted criteria [7–10]. The study
was approved by the NJH Institutional Review Board
(IRB; study #2868) which waived the requirement for
written, informed consent.
6MWT
The 6MWT was conducted similarly in all patients
(whether users or non-users), by trained technicians at
NJH, according to published guidelines with slight modi-
fication [11]. Per standard operating procedure at NJH,
the 6MWT is terminated if SpO2 drops below 80 %. To
maintain reliability in the 6MWT outcome of most
interest (distance), we tried to hold constant as many
other variables as possible. Thus, a patient performed
all 6MWT on the same O2 l flow, unless or until he was
unable to walk for a full six minutes without SpO2 fall-
ing below 80 %. We included in our analyses data only
from patients who walked for a full six minutes. For
patients who completed multiple 6MWT, we selected the
first test. Ratings for dyspnea and exertion were assessed
immediately after completion of the test by the technician
and using the CR10 Borg scale (range 0–10, with higher
scores connoting greater dyspnea or exertion as appropri-
ate) [12]. The minimal clinically important difference for
the Borg scale is reported to be one point [13].
Statistical analysis
Summary statistics were generated for baseline data with
the sample stratified on whether O2 was used (users) or
not (non-users) during the 6MWT. Student’s t-tests were
used for between-groups comparisons of continuous vari-
ables. Cochran-Mantel-Haenszel, Chi square or Fisher’s
exact tests were used as appropriate for between-groups
comparisons of categorical variables. We used Pearson
correlation coefficients to express associations between
dyspnea ratings and other variables. We used linear re-
gression to examine associations between dyspnea ratings
and other variables while controlling for potentially influen-
tial predictors. We considered p < 0.05 to represent stat-
istical significance. Analyses were performed using SAS
version 9.3 statistical software (SAS, Inc.; Cary, NC).
Results
The study group comprised 812 users and 514 non-
users. On average, users were older, had greater impair-
ments in pulmonary physiology and had shorter 6MWD
than non-users. Despite a similar SpO2 at six minutes
(88.1 % vs. 88.7 %), users perceived significantly greater
dyspnea than non-users (Table 1).
In both users and non-users, dyspnea was correlated
with certain other variables; however, all correlations
were weak (Table 2). In both subgroups, dyspnea was in-
versely correlated with 6MWD. Among the 791 subjects
whose SpO2 fell below 89 %, there were nearly twice as
many users as non-users (Table 3). Although the SpO2
at six minutes was similar (85.3 % vs. 86.0 %), dyspnea
ratings among users were significantly higher than in
non-users. The same was true for subjects whose SpO2
remained 89 % or greater for the duration of the 6MWT:
despite identical mean SpO2 values at six minutes (91.4 %
vs. 91.4 %), dyspnea ratings were significantly higher
among users than in non-users (Table 4).
Results were similar for the 883 subjects (572 users
and 311 non-users) with a history of smoking: the SpO2
values at six minutes were similar (87.9 % vs. 88.4 %),
and dyspnea ratings were higher among users than in
non-users (3.8 ± 2.0 vs. 2.9 ± 1.7, p < 0.0001). For the 473
subjects (303 users and 170 non-users) with IPF, the SpO2
values at six minutes were the same (86.7 % vs. 86.9 %),
and dyspnea ratings were higher among users than in non-
users (3.8 ± 2.1 vs. 2.9 ± 1.6, p < 0.0001). Among the 118
subjects whose SpO2 never dropped by more than three
Cao et al. Multidisciplinary Respiratory Medicine  (2015) 10:37 Page 2 of 6
points from baseline (rest), although minute-six SpO2 was
higher in users than in non-users, dyspnea ratings among
users were significantly higher than in non-users (Table 5).
Results from the linear regression analysis are pre-
sented in Table 6. While controlling for various combina-
tions of predictors, O2 use remained a significant predictor
of dyspnea rating. As revealed by the R-squared values,
none of the combinations of variables explained more than
minimal variance in dyspnea ratings.
Discussion
We examined patients with fILD and found that those
who used O2 during a 6MWT consistently experienced
more severe dyspnea than those who did not use O2.
Data on the effects of O2 in patients with fILD are sur-
prisingly limited, and much of the information on the
potential benefits of O2 that is used in clinical decision-
making with fILD patients, is based solely on scientific
rationale or borrowed from the COPD literature. In two
Letters to the Editor, investigators described the re-
sults of retrospective studies in which they examined
the within-subject beneficial effects of O2 on various
outcome measures collected around 6MWTs [5, 6]. In
one study, investigators observed that, in 52 patients
with fILD, during a second 6MWT for which O2 was
administered according to a semi-quantitative algo-
rithm aimed at maintaining SpO2 at (closer-to) accept-
able levels, distance walked, nadir SpO2 and Borg
Table 1 Baseline characteristics for O2 users and O2 non-users
with fILDs
O2 (N = 812) No O2 (N = 514) P-
Age (years) 68.3 ± 10.5 66.6 ± 11.0 0.004
Female (%) 327 (40.3) 211 (41.1) 0.78
Smoking* 4 (0.6 %) 3 (0.6 %) 0.003
Present 471 (65.9 %) 277 (57.4 %)
Past 240 (33.6 %) 203 (42.0 %)
Never
BMI 30.3 ± 6.9 28.5 ± 5.5 <0.0001
IPF diagnosis (%) 303 (37.3) 170 (33.1) 0.12
FVC% within 30 days** 61.3 ± 18.9 77.5 ± 17.4 <0.0001
DLCO% within 30 days*** 37.5 ± 12.8 56.1 ± 16.5 <0.0001
6MWD (feet) 1070.6 ± 361.4 1421.4 ± 343.7 <0.0001
Borg Dyspnea 3.9 ± 2.0 2.9 ± 1.7 <0.0001
Borg Exertion**** 3.2 ± 2.1 2.4 ± 1.8 <0.0001
HR baseline 79.7 ± 13.9 78.1 ± 13.2 0.03
HR at 6 min 109.7 ± 15.9 110.9 ± 15.8 0.18
HR rise 30.0 ± 14.5 32.8 ± 13.7 0.0004
SpO2 baseline 97.4 ± 1.9 95.2 ± 1.7 <0.0001
SpO2 at 6 min 88.1 ± 5.3 88.7 ± 5.4 0.04
SpO2 drop 9.2 ± 5.5 6.4 ± 5.2 <0.0001
Values are mean and standard deviation or count (percent); IPF idiopathic
pulmonary fibrosis; BMI body mass index; FVC% percent predicted forced vital
capacity; DLCO% percent predicted diffusing capacity of the lung for carbon
monoxide; 6MWD distance walked during six-minute walk test (6MWT); SpO2
peripheral oxygen saturation; HR heart rate; O2 completed 6MWT using
supplemental oxygen; No O2 completed 6MWT without using supplemental
oxygen; *N= 715 for O2 users and 483 for non-users; **N= 446 for O2 users and
251 for non-users; ***N= 211 for O2 users and 123 for non-users; ****N= 672 for
O2 users and 415 for non-users
Table 2 Correlation between dyspnea rating and other
variables for O2 users and O2 non-users





HR baseline 0.07 0.03
0.04 0.53
HR at 6 min 0.08 0.16
0.02 0.0003
HR rise 0.02 0.15
0.49 0.0003
SpO2 baseline 0.03 −0.14
0.47 0.002
SpO2 at 6 min −0.19 −0.21
<0.0001 <0.0001
SpO2 drop −0.19 −0.17
<0.0001 <0.0001
Values are correlation coefficient (top) and p value (bottom); BMI body
mass index; 6MWD distance walked during six-minute walk test (6MWT);
HR heart rate; SpO2 peripheral oxygen saturation; O2 completed 6MWT
using supplemental oxygen; 6MWD distance walked during six-minute
walk test (6MWT); O2 completed 6MWT using supplemental oxygen;
No O2 completed 6MWT without using supplemental oxygen
Table 3 Dyspnea and other results for O2 users and O2
non-users among subjects whose nadir SpO2 was < 89 %
O2 (N = 439) No O2 (N = 252) P
6MWD (feet) 1051 ± 382.7 1415.1 ± 370.5 <0.0001
BMI 30.2 ± 6.8 28.8 ± 5.2 0.003
Borg Dyspnea 4.3 ± 2.0 3.4 ± 1.7 <0.0001
Borg Exertion* 3.5 ± 2.1 2.7 ± 1.8 <0.0001
HR baseline 80.4 ± 13.7 78.2 ± 13.3 0.04
HR at 6 min 112.3 ± 16.0 112.9 ± 16.2 0.62
HR rise 31.9 ± 14.8 34.7 ± 15.3 0.02
SpO2 baseline 97.2 ± 2.0 94.6 ± 1.7 <0.0001
SpO2 at 6 min 85.3 ± 3.5 86.0 ± 3.2 0.02
SpO2 drop 11.8 ± 4.1 8.6 ± 3.3 <0.0001
Values are mean and standard deviation; 6MWD distance walked during six-minute
walk test (6MWT), O2 completed 6MWT using supplemental oxygen, No O2
completed 6MWT without using supplemental oxygen, SpO2 peripheral oxygen
saturation; *N= 355 for O2 users and 204 for non-users
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score improved (by one point) over values obtained
during a baseline 6MWT. The results were similar for
the subgroup of subjects with either idiopathic pulmonary
fibrosis (IPF) or NSIP, in whom O2 administration resulted
in improved dyspnea (median Borg scores dropped from
4.25 to 3.25) and in the nadir SpO2 increasing from 75 to
83 %. In the other study of 70 subjects (all with IPF), Frank
and her colleagues found that, compared to a baseline
6MWT performed on ambient air or with inadequate O2
flow, administering O2 led to increased distance walked
and improved nadir SpO2, but dyspnea did not change
(mean Borg score 4.8 ± 2.1 vs. 4.5 ± 2.2) [5].
Dyspnea is a complex perception that depends on the
integration of multiple inputs from several sources. Blood
oxygen level is but one of those sources, and the weak
correlation we observed between dyspnea rating and
minute-six SpO2 affirms it is far from the main contributor.
Other contributors include neural inputs arising from re-
ceptors in the airways and lung parenchyma, peripheral
locomotor and respiratory muscles, and central and
peripheral chemoreceptors, along with corollary neuronal
discharge arising from the brainstem and cortical motor
centers [14].
In our study, patients who used O2 consistently started
with a higher SpO2 than non-users, and although SpO2
declined to a greater degree during the walk in users
than non-users (9 % vs. 6 %), minute-six SpO2 was the
same in both groups (88 %). Perhaps has dyspnea more
to do with SpO2 decline from baseline than the absolute
SpO2 at the time of dyspnea rating? Our results suggest
this is not the case: the correlation between dyspnea and
SpO2 decline was the same (weak) as the correlation
between dyspnea and minute-six SpO2. However, in the
subgroup of patients who did not desaturate at all
during the walk (SpO2 decline < 4 points), despite O2
users having a higher minute-six SpO2 than non-users
(95 % vs. 93 %), O2 users perceived greater dyspnea
(mean Borg scores 3.4 vs. 2.4).
In our statistical models controlling for either minute-
six (data not shown) or decline-from-baseline in SpO2
(i.e., SpO2 drop), each of these SpO2 measures was a sig-
nificant predictor of dyspnea, and in each model, O2 use
remained an independent predictor of dyspnea. How-
ever, each model explained minimal variance in dyspnea
scores—again, confirming that dyspnea relies on more
inputs than simply blood oxygen.
We suspect users in our study perceived greater
dyspnea intensity than non-users because of a complex
interaction of elements, including those related to con-
duct of the 6MWT and perhaps certain neurophysio-
logical factors. At our center, in an attempt to maintain
reliability in the 6MWT outcome of most interest
(distance), we try to hold constant as many other vari-
ables as possible. Thus, a patient performs all 6MWT on
the same O2 l flow, unless or until he is unable to walk
for a full six minutes (in which case flow is reset for
subsequent 6MWTs). Because of this practice, on certain
occasions, patients at our center may perform their
6MWT on O2 l flows below what they use with exertion
at home. In our study, this “intentional under-dosing” of
O2 flow—to maintain reliability—could have driven
dyspnea ratings up in O2 users. Unfortunately, with this
data set, we are unable to determine when this under-
dosing might have occurred. Regardless, this “intentional
under-dosing” explanation would seem not to apply to
subjects whose O2 was dosed adequately enough to
maintain an acceptable SpO2 throughout the test, includ-
ing the over 600-patient subgroup whose SpO2 remained
above 88 %, or the greater than 100-patient subgroup
Table 4 Dyspnea and other results for O2 users and O non-users
among subjects whose nadir SpO2 was 89 % or greater
(nadir SpO2≥ 89 %)
O2 (N = 373) No O2 (N = 262) P
6MWD 1092.4 ± 333.8 1427.4 ± 316.4 <0.0001
BMI 30.4 ± 6.9 28.2 ± 5.8 <0.0001
Borg Dyspnea 3.4 ± 1.9 2.4 ± 1.6 <0.0001
Borg Exertion* 2.9 ± 2.1 2.2 ± 1.7 <0.0001
HR baseline 79.0 ± 14.0 78.0 ± 13.0 0.37
HR at 6 min 106.7 ± 15.3 109.0 ± 15.1 0.06
HR rise 27.7 ± 13.7 31.0 ± 11.8 0.001
SpO2 baseline 97.6 ± 1.7 95.7 ± 1.6 <0.0001
SpO2 at 6 min 91.4 ± 5.2 91.4 ± 5.7 0.97
SpO2 drop 6.5 ± 2.4 4.6 ± 1.9 <0.0001
Values are mean and standard deviation; 6MWD distance walked during
six-minute walk test (6MWT), O2 completed 6MWT using supplemental
oxygen, No O2 completed 6MWT without using supplemental oxygen,
HR heart rate, SpO2 peripheral oxygen saturation; *N = 317 for O2 users
and 211 for non-users
Table 5 Dyspnea and other results for O2 users and O2 non-users
among subjects whose SpO2 fell by <4 % during the walk
O2 (N = 36) No O2 (N = 82) P
6MWD (feet) 944.9 ± 367.0 1385.3 ± 322.4 <0.0001
BMI 31.6 ± 6.8 27.6 ± 5.3 0.001
Borg Dyspnea 3.3 ± 1.6 2.3 ± 1.7 0.005
Borg Exertion* 2.7 ± 2.0 2.2 ± 1.7 0.20
HR baseline 81.3 ± 15.3 79.9 ± 14.7 0.64
HR at 6 min 99.6 ± 11.7 107.6 ± 15.6 0.007
HR rise 18.2 ± 16.1 27.6 ± 10.5 0.002
SpO2 baseline 96.6 ± 2.5 95.2 ± 1.9 0.0009
SpO2 at 6 min 95.2 ± 2.3 93.4 ± 2.1 <0.0001
SpO2 drop 1.1 ± 3.1 1.8 ± 1.0 0.18
Values are mean and standard deviation; 6MWD distance walked during six-minute
walk test (6MWT), O2 completed 6MWT using supplemental oxygen, No O2
completed 6MWT without using supplemental oxygen, HR heart rate, SpO2
peripheral oxygen saturation; *N = 30 for O2 users and 67 for non-users
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whose saturations did not decline at all. In both these
subgroups, O2 users rated their dyspnea as more intense
than non-users.
Also at our center, patients who use O2 at home either
carry or pull their O2 delivery device while completing
their 6MWT. Having to move this excess weight over
distance—or altered chest wall mechanics resulting from
carrying or pulling the device—could add to dyspnea. To
our knowledge, this has yet to be examined, but we
believe it deserves investigation. If carrying or pulling the
delivery device is found to add significantly to dyspnea in-
tensity, this could be a target for therapeutic intervention.
Another alternative explanation is that dyspnea truly
depends greatly on arterial oxygen but SpO2 was an
especially inaccurate reflection of it in this cohort; we
doubt this was the case, but if it were, we would expect
the inaccuracies to affect both users and non-users
equally. We excluded patients with underlying CTD in
the hopes of limiting the influence of vascular abnormal-
ities like Raynaud’s or pulmonary hypertension.
Various physical factors unrelated to the lungs, SpO2 or
other aspects of oxygen delivery also must be considered as
potential explanations for our results. While exerting
(and into recovery), subnormal lung compliance in pa-
tients with ILD induces rapid-shallow breathing. The
physical sensation—and mental/emotional impact—of
this breathing pattern, which occurs to some degree
when patients with ILD exert to any degree, is expected
to influence dyspnea ratings. How subjects internally
considered, weighed and integrated each component
(physical or mental/emotional) as they made their ratings
for “breathlessness” is unknown. Compared with non-
users, O2 users had lower FVC% and, by deduction, lower
lung compliance than non-users—a factor expected to
hasten and heighten rapid-shallow breathing. We do not
measure respiratory rate during the 6MWT at our center,
so we are unable to determine whether O2 users had
higher respiratory rates than non-users. Additional studies
aimed at discerning whether or how much respiratory rate
(and other physical or emotional components) contributes
to exertional dyspnea ratings are needed. Although we are
unable to comment on directly-observed respiratory
rate, FVC% as a marker of lung compliance could be
considered a reasonable surrogate for respiratory rate.
In statistical models that included O2 use, and controlled
for FVC%, O2 use remained a significant predictor of
dyspnea. In a comprehensive appraisal of dyspnea in
patients with chronic interstitial lung disease, Faisal
and colleagues observed that dyspnea intensity during
exertion climbed as inspiratory neural drive increased
and tidal volume became constrained (thus blunting
the mechanical respiratory response during exercise)
[15].
Another consideration is whether the greater disease
severity in O2 users might have contributed to physical
inactivity and deconditioning. Given the practical chal-
lenges of using O2 and the possibility that it prohibits
patients from living a more active, carefree lifestyle, we
suspect that, on average, fILD patients who require O2
are less physically active (and thus less well-conditioned)
than patients who do not require O2. De-conditioned
skeletal muscles are less efficient and fatigue-resistant
Table 6 Linear regression models showing association between dyspnea ratings and other variables
Model 1 Model 2 Model 3 Model 4 Model 5
Intercept 2.50 ± 0.10 3.31 ± 0.26 3.24 ± 0.27 5.37 ± 0.31 1.96 ± 0.36
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Used O2 0.77 ± 0.11 0.66 ± 0.12 0.68 ± 0.12 0.42 ± 0.13 0.54 ± 0.12
<0.0001 <0.0001 <0.0001 0.001 <0.0001
BMI 0.05 ± 0.01
<0.0001
SpO2 drop 0.07 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.06 ± 0.01
<0.0001 <0.0001 <0.0001 <0.0001
FVC% −0.01 ± 0.003 −0.01 ± 0.003 −0.01 ± 0.0002 −0.01 ± 0.002
0.001 0.001 0.008 <0.0001
6MWD −0.001 ± 0.002
<0.0001
HR rise 0.003 ± 0.004
0.43
R-square 0.09 0.09 0.09 0.11 0.11
Values are coefficients and standard error (top) and p value (bottom); 6MWD distance walked during six-minute walk test (6MWT), O2 completed 6MWT using
supplemental oxygen, No O2 completed 6MWT without using supplemental oxygen, HR heart rate, SpO2 peripheral oxygen saturation
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than conditioned muscles, and peripheral locomotor [14]
muscle fatigue contributes to dyspnea. Compared with
non-users, O2 users walked shorter distances during the
6MWT; this was true even for the subgroup that did not
desaturate to < 89 %. Whether the shorter distance walked
was due to deconditioning or some other factor(s) is un-
known; however, deconditioning could well explain the in-
teresting and perhaps somewhat paradoxical finding that
dyspnea severity was inversely correlated with 6MWD:
subjects who walked further, were better conditioned and
thus perceived less dyspnea.
Conclusion
Dyspnea is a complex perception that impacts the lives of
patients with fILD. It is important for a patient with fILD
to know what to expect when being prescribed O2: it will
likely decrease dyspnea (compared with not using O2), but
because dyspnea is driven by so many inputs (with SpO2
being just one), O2 will not resolve dyspnea. Further re-
search is needed to better understand the mechanisms
driving dyspnea in patients with fILD and to devise strat-
egies to lessen it.
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